Sodium–glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin–metformin

References

• World Health Organization Obesity and Overweight Geneva, Switzerland World Health Organization 2015 Available from: http://www.who.int/mediacentre/factsheets/fs311/en/ Accessed August 30, 2015
   Google Scholar
• International Diabetes Federation Diabetes: Facts and Figures Brussels, Belgium International Diabetes Federation 2014 Available from: https://www.idf.org/worlddiabetesday/toolkit/gp/facts-figures Accessed August 30, 2015
   Google Scholar
• Kahn SE Cooper ME Del Prato S Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future Lancet 2014 383 9922 1068 1083 24315620
   PubMed Web of Science ®Google Scholar
• Fonseca VA Defining and characterizing the progression of type 2 diabetes Diabetes Care 2009 32 Suppl 2 S151 S156 19875543
   PubMed Web of Science ®Google Scholar
• DeFronzo R Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus Diabetes 2009 58 4 773 795 19336687
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention National Diabetes Statistics Report: Estimates of Diabetes and its Burden in the United States, 2014 Atlanta, GA Centers for Disease Control and Prevention 2014 Available from: http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf Accessed September 23, 2015
   Google Scholar
• Wing RR Lang W Wadden TA Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes Diabetes Care 2011 34 7 1481 1486 21593294
   PubMed Web of Science ®Google Scholar
• Nathan DM Buse JB Davidson MB Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the study of diabetes Diabetes Care 2009 32 1 193 203 18945920
   PubMed Web of Science ®Google Scholar
• Ali MK Bullard KM Saaddine JB Cowie CC Imperatore G Gregg EW Achievement of goals in US diabetes care, 1999–2010 N Engl J Med 2013 368 17 1613 1624 23614587
   PubMed Web of Science ®Google Scholar
• Stark Casagrande S Fradkin JE Saydah SH Rust KF Cowie CC The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988–2010 Diabetes Care 2013 36 8 2271 2279 23418368
   PubMed Web of Science ®Google Scholar
• Gerstein HC Swedberg K Carlsson J The hemoglobin A1C level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program Arch Intern Med 2008 168 15 1699 1704 18695086
   PubMedGoogle Scholar
• Selvin E Marinopoulos S Berkenblit G Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus Ann Intern Med 2004 141 6 421 431 15381515
   PubMed Web of Science ®Google Scholar
• Stratton IM Adler AI Neil HA Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ 2000 321 7258 405 412 10938048
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N Engl J Med 1993 329 14 977 986 8366922
   PubMed Web of Science ®Google Scholar
• Nathan DM Cleary PA Backlund JY Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes N Engl J Med 2005 353 25 2643 2653 16371630
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 1998 352 9131 837 853 9742976
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 1998 352 9131 854 865 9742977
   PubMed Web of Science ®Google Scholar
• Gaede P Vedel P Larsen N Jensen GV Parving HH Pedersen O Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N Engl J Med 2003 348 5 383 393 12556541
   PubMed Web of Science ®Google Scholar
• Gaede P Lund-Andersen H Parving HH Pedersen O Effect of a multi-factorial intervention on mortality in type 2 diabetes: results and projections from the Steno-2 study N Engl J Med 2008 358 6 580 591 18256393
   PubMed Web of Science ®Google Scholar
• Holman RR Paul SK Bethel MA Matthews DR Neil HA 10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 2008 359 15 1577 1589 18784090
   PubMed Web of Science ®Google Scholar
• Gerstein HC Miller ME Byington RP Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 2008 358 24 2545 2559 18539917
   PubMed Web of Science ®Google Scholar
• Duckworth W Abraira C Moritz T Glucose control and vascular complications in veterans with type 2 diabetes N Engl J Med 2009 360 2 129 139 19092145
   PubMed Web of Science ®Google Scholar
• Patel A MacMahon S Chalmers J Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 2008 358 24 2560 2572 18539916
   PubMed Web of Science ®Google Scholar
• Riddle MC Ambrosius WT Brillon DJ Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial Diabetes Care 2010 33 983 990 20427682
   PubMed Web of Science ®Google Scholar
• Bonds DE Miller ME Bergenstal RM The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study BMJ 2010 340 b4909 20061358
   PubMed Web of Science ®Google Scholar
• Seaquist ER Miller ME Bonds DE The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study Diabetes Care 2012 35 2 409 414 22179956
   PubMed Web of Science ®Google Scholar
• Fonseca V McDuffie R Calles J Determinants of weight gain in the action to control cardiovascular risk in diabetes trial Diabetes Care 2013 36 8 2162 2168 23412077
   PubMed Web of Science ®Google Scholar
• Siraj ES Rubin DJ Riddle MC Insulin dose and cardiovascular mortality in the ACCORD trial Diabetes Care 2015 38 11 2000 2008 26464212
   PubMed Web of Science ®Google Scholar
• Khunti K Wolden ML Thorsted BL Andersen M Davies MJ Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people Diabetes Care 2013 36 11 3411 3417 23877982
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Standards of medical care in diabetes-2015 Diabetes Care 2015 38 Suppl 1 S88 S89
   Google Scholar
• Garber AJ Abrahamson MJ Barzilay JI AACE/ACE comprehensive diabetes management algorithm 2015 Endocr Pract 2015 21 4 e1 e10
   Web of Science ®Google Scholar
• DeFronzo RA Eldor R Abdul-Ghani M Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes Diabetes Care 2013 36 Suppl 2 S127 S138 23882037
   PubMed Web of Science ®Google Scholar
• Gerich JE Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications Diabet Med 2010 27 2 136 142 20546255
   PubMed Web of Science ®Google Scholar
• Wilding JP The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors Metabolism 2014 63 10 1228 1237 25104103
   PubMed Web of Science ®Google Scholar
• DeFronzo RA Hompesch M Kasichayanula S Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes Diabetes Care 2013 36 10 3169 3176 23735727
   PubMed Web of Science ®Google Scholar
• Whaley JM Tirmenstein M Reilly TP Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus Diabetes Metab Syndr Obes 2012 5 135 148 22923998
   PubMedGoogle Scholar
• Bolinder J Ljunggren O Kullberg J Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin J Clin Endocrinol Metab 2012 97 3 1020 1031 22238392
   PubMed Web of Science ®Google Scholar
• Lambers Heerspink HJ de Zeeuw D Wie L Leslie B List J Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes Diabetes Obes Metab 2013 15 9 853 862 23668478
   PubMed Web of Science ®Google Scholar
• Calado J Santer R Rueff J Effect of kidney disease on glucose handling (including genetic defects) Kidney Int Suppl 2011 120 S7 S13 21358700
   PubMed Web of Science ®Google Scholar
• Del Prato S Nauck M Duran-Garcia S Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data Diabetes Obes Metab 2015 17 6 581 590 25735400
   PubMed Web of Science ®Google Scholar
• Bailey CJ Gross JL Hennicken D Iqbal N Mansfield TA List JF Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial BMC Med 2013 11 43 23425012
   PubMed Web of Science ®Google Scholar
• Bolinder J Ljunggren O Johansson L Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin Diabetes Obes Metab 2014 16 2 159 169 23906445
   PubMed Web of Science ®Google Scholar
• Wilding JP Woo V Rohwedder K Sugg J Parikh S Dapagliflozin 006 Study G Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years Diabetes Obes Metab 2014 16 2 124 136 23911013
   PubMed Web of Science ®Google Scholar
• Astra Zeneca Multicenter trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events (DECLARE-TIMI58) NLM identifier: NCT01730534. Available from: https://clinicaltrials.gov/ct2/show/NCT01730534 Accessed September 22, 2015
   Google Scholar
• Zinman B Wanner C Lachin JM Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes N Engl J Med 2015 373 22 2117 2128 26378978
   PubMed Web of Science ®Google Scholar
• Neal B Perkovic V de Zeeuw D Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS) – a randomized placebo-controlled trial Am Heart J 2013 166 2 217 223.e211 23895803
   PubMed Web of Science ®Google Scholar
• Ferrannini E Muscelli E Frascerra S Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients J Clin Invest 2014 124 2 499 508 24463454
   PubMed Web of Science ®Google Scholar
• Merovci A Solis-Herrera C Daniele G Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production J Clin Invest 2014 124 2 509 514 24463448
   PubMed Web of Science ®Google Scholar
• Bonner C Kerr-Conte J Gmyr V Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion Nat Med 2015 21 5 512 517 25894829
   PubMed Web of Science ®Google Scholar
• Witters LA The blooming of the French lilac J Clin Invest 2001 108 8 1105 1107 11602616
   PubMed Web of Science ®Google Scholar
• Madiraju AK Erion DM Rahimi Y Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase Nature 2014 510 7506 542 546 24847880
   PubMed Web of Science ®Google Scholar
• Stephenne X Foretz M Taleux N Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status Diabetologia 2011 54 12 3101 3110 21947382
   PubMed Web of Science ®Google Scholar
• Zhou G Myers R Li Y Role of AMP-activated protein kinase in mechanism of metformin action J Clin Invest 2001 108 8 1167 1174 11602624
   PubMed Web of Science ®Google Scholar
• Viollet B Guigas B Sanz Garcia N Leclerc J Foretz M Andreelli F Cellular and molecular mechanisms of metformin: an overview Clin Sci (Lond) 2012 122 6 253 270 22117616
   PubMed Web of Science ®Google Scholar
• Glucophage^® (Metformin HCl tablets) and Glucophage XR® (Metformin HCl) extended-release tablets [prescribing information] Princeton, NJ Bristol-Myers Squibb Company 2009
   Google Scholar
• Mannucci E Ognibene A Cremasco F Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects Diabetes Care 2001 24 3 489 494 11289473
   PubMed Web of Science ®Google Scholar
• Mulherin AJ Oh AH Kim H Grieco A Lauffer LM Brubaker PL Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell Endocrinology 2011 152 12 4610 4619 21971158
   PubMed Web of Science ®Google Scholar
• Buse JB DeFronzo RA Rosenstock J The primary glucose-lowering effect of metformin resides in the gut, not the circulation. Results from short-term pharmacokinetic and 12-week dose-ranging studies Diabetes Care 2015 39 2 198 205 26285584
   PubMed Web of Science ®Google Scholar
• Napolitano A Miller S Nicholls AW Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus PLoS One 2014 9 7 e100778 24988476
   PubMed Web of Science ®Google Scholar
• Bailey CJ Gross JL Pieters A Bastien A List JF Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial Lancet 2010 375 9733 2223 2233 20609968
   PubMed Web of Science ®Google Scholar
• Wilding JP Woo V Soler NG Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial Ann Intern Med 2012 156 6 405 415 22431673
   PubMed Web of Science ®Google Scholar
• Katz A Yeh HC Efficacy and safety of dapagliflozin in patients with type 2 diabetes on insulin ± metformin regimens Diabetes 2015 64 Suppl 1 A317
   Google Scholar
• Nauck MA Del Prato S Meier JJ Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial Diabetes Care 2011 34 9 2015 2022 21816980
   PubMed Web of Science ®Google Scholar
• Nauck MA Del Prato S Duran-Garcia S Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin Diabetes Obes Metab 2014 16 11 1111 1120 24919526
   PubMed Web of Science ®Google Scholar
• Henry RR Murray AV Marmolejo MH Hennicken D Ptaszynska A List JF Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial Int J Clin Pract 2012 66 5 446 456 22413962
   PubMed Web of Science ®Google Scholar
• Rosenstock J Hansen L Zee P Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin Diabetes Care 2015 38 3 376 383 25352655
   PubMed Web of Science ®Google Scholar
• Sjostrom CD Johansson P Ptaszynska A List J Johnsson E Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes Diab Vasc Dis Res 2015 12 5 352 358 26008804
   PubMed Web of Science ®Google Scholar
• Sjostrom CD Hashemi M Sugg J Ptaszynska A Johnsson E Dapagliflozin-induced weight loss affects 24-week glycated haemoglobin and blood pressure levels Diabetes Obes Metab 2015 17 8 809 812 25997813
   PubMed Web of Science ®Google Scholar
• Geerlings S Fonseca V Castro-Diaz D List J Parikh S Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria Diabetes Res Clin Pract 2014 103 3 373 381 24529566
   PubMed Web of Science ®Google Scholar
• Johnsson KM Ptaszynska A Schmitz B Sugg J Parikh SJ List JF Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin J Diabetes Complications 2013 27 5 479 484 23806570
   PubMed Web of Science ®Google Scholar
• Johnsson KM Ptaszynska A Schmitz B Sugg J Parikh SJ List JF Urinary tract infections in patients with diabetes treated with dapagliflozin J Diabetes Complications 2013 27 5 473 478 23849632
   PubMed Web of Science ®Google Scholar
• US Food Drug Administration FDA Drug Safety Communication: FDA Revises Labels of SGLT2 Inhibitors for Diabetes to Include Warnings about too Much Acid in the Blood and Serious Urinary Tract Infections Silver Spring, MD US Food and Drug Administration 2015 Available from: http://www.fda.gov/Drugs/DrugSafety/ucm475463.htm Accessed February 16, 2016
   Google Scholar
• Farxiga^® (Dapagliflozin) [prescribing information] Wilmington, DE AstraZeneca 2015
   Google Scholar
• Rosenstock J Ferrannini E Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors Diabetes Care 2015 38 9 1638 1642 26294774
   PubMed Web of Science ®Google Scholar
• Westerberg DP Diabetic ketoacidosis: evaluation and treatment Am Fam Physician 2013 87 5 337 346 23547550
   PubMed Web of Science ®Google Scholar
• Peters AL Buschur EO Buse JB Cohan P Diner JC Hirsch IB Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition Diabetes Care 2015 38 9 1687 1693 26078479
   PubMed Web of Science ®Google Scholar
• American Association of Clinical Endocrinologists AACE/ACE Scientific and Clinical Review: Association of SGLT2 Inhibitors and DKA 2015 Available from: http://resources.aace.com/in-the-news/aaceace-scientific-and-clinical-review-association-sglt2-inhibitors-and-dka Accessed January 11, 2016
   Google Scholar
• Curkendall SM Thomas N Bell KF Juneau PL Weiss AJ Predictors of medication adherence in patients with type 2 diabetes mellitus Curr Med Res Opin 2013 29 10 1275 1286 23815104
   PubMed Web of Science ®Google Scholar
• Tiv M Viel JF Mauny F Medication adherence in type 2 diabetes: the ENTRED study 2007, a French Population-Based Study PLoS One 2012 7 3 e32412 22403654
   PubMed Web of Science ®Google Scholar
• Zhu VJ Tu W Rosenman MB Overhage JM Nonadherence to oral antihyperglycemic agents: subsequent hospitalization and mortality among patients with type 2 diabetes in clinical practice Stud Health Technol Inform 2015 216 60 63 26262010
   PubMedGoogle Scholar
• Grandy S Langkilde AM Sugg JE Parikh S Sjostrom CD Health-related quality of life (EQ-5D) among type 2 diabetes mellitus patients treated with dapagliflozin over 2 years Int J Clin Pract 2014 68 4 486 494 24499168
   PubMed Web of Science ®Google Scholar
• Grandy S Hashemi M Langkilde AM Parikh S Sjostrom CD Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin Diabetes Obes Metab 2014 16 7 645 650 24443876
   PubMed Web of Science ®Google Scholar
• Selvin E Francis LM Ballantyne CM Nontraditional markers of glycemia: associations with microvascular conditions Diabetes Care 2011 34 4 960 967 21335368
   PubMed Web of Science ®Google Scholar